Evotec/$EVO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Evotec
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
Ticker
$EVO
Sector
Primary listing
Employees
4,467
Headquarters
Website
Evotec Metrics
BasicAdvanced
$1.1bn
-
-$0.69
1.30
-
Price and volume
Market cap
$1.1bn
Beta
1.3
52-week high
$4.80
52-week low
$2.31
Average daily volume
108k
Financial strength
Current ratio
2.073
Quick ratio
1.845
Long term debt to equity
42.277
Total debt to equity
55.019
Profitability
EBITDA (TTM)
10.305
Gross margin (TTM)
14.49%
Net profit margin (TTM)
-13.13%
Operating margin (TTM)
-8.38%
Effective tax rate (TTM)
-19.31%
Revenue per employee (TTM)
$212,150
Management effectiveness
Return on assets (TTM)
-2.28%
Return on equity (TTM)
-11.72%
Valuation
Price to revenue (TTM)
0.587
Price to book
1.13
Price to tangible book (TTM)
1.81
Price to free cash flow (TTM)
-5.038
Free cash flow yield (TTM)
-19.85%
Free cash flow per share (TTM)
-0.609
Growth
Revenue change (TTM)
-1.08%
Earnings per share change (TTM)
-47.48%
3-year revenue growth (CAGR)
1.61%
10-year revenue growth (CAGR)
19.97%
3-year earnings per share growth (CAGR)
-16.30%
10-year earnings per share growth (CAGR)
17.12%
What the Analysts think about Evotec
Analyst ratings (Buy, Hold, Sell) for Evotec stock.
Evotec Financial Performance
Revenues and expenses
Evotec Earnings Performance
Company profitability
Evotec News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Evotec stock?
Evotec (EVO) has a market cap of $1.1B as of May 11, 2026.
What is the P/E ratio for Evotec stock?
The price to earnings (P/E) ratio for Evotec (EVO) stock is 0 as of May 11, 2026.
Does Evotec stock pay dividends?
No, Evotec (EVO) stock does not pay dividends to its shareholders as of May 11, 2026.
When is the next Evotec dividend payment date?
Evotec (EVO) stock does not pay dividends to its shareholders.
What is the beta indicator for Evotec?
Evotec (EVO) has a beta rating of 1.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.